The National Institute for Health and Care Excellence's Scientific Advice service will be launching an online tool on July 3 for developers of medical devices and diagnostics. Find out more here. (Source: MTRC, 6/1/17) […]
HE.Com’s Weekly News is Here! What Did You Miss?
What impact will ICER reports have in Europe? Should value frameworks for rare disease be different? How is the current uncertainty in healthcare affecting you? Could your advisory board benefit from a medical writer? Read more about all of these topics and more in HealthEconomics.Com's latest […]
CEAs Disproportionately Conducted on Pharmaceuticals
The Cost-effectiveness analysis (CEA) has become an important tool for assessing health care efficiency, however, researchers have recently found that the application of CEA across different types of health care interventions is imbalanced. Why does this imbalance exist? How can government policies […]
ICER and UIC Form a Cost-Effectiveness Collaboration
The Institute for Clinical and Economic Review has formed a partnership with the University of Illinois at Chicago (UIC) to evaluate the cost-effectiveness of new drugs and other health care interventions. Find out more on this collaboration here. (Source: ICER, 4/14/17) […]
Cancer Experts Condemn Recent NICE Decision
The National Institute for Health and Care Excellence recently issued a new draft guidance refusing to recommend nivolumab for the treatment of head and neck cancer. Expert cancer clinicians however, have condemned the decision. Find out more here. (Source: Adrian O'Dowd, onmedica, 4/11/17) […]
ICER Says Humira Needs 50-69% Discount
The Institute for Clinical and Economic Review recently evaluated rheumatoid arthritis drugs and awarded AbbVie's Humira a "C" rating in their comparative effectiveness analysis. According to the report, Humira would need a net price discount of 50% to 69% to be cost-effective. Find out more here. […]
ICER to Produce a “New Evidence Update” for PCSK9 Inhibitors
Important new clinical evidence is now available related to the Institute for Clinical and Economic Review (ICER)'s 2015 review of PCSK9 Inhibitors, and has inspired work on a New Evidence Update. The update is expected to be available in mid-May of 2017. Find out more here. (Source: ICER) […]
Just Published – 18th Issue of the HERC Quarterly Newsletter
The 18th issue of the Health Economics Research Centre (HERC) quarterly Newsletter has just recently been published. You'll find articles on the cost-effectiveness of models of hip fracture care, Economic impact of early intervention in psychosis services, Reforms at the Scottish Medicines […]
Video: Recommendations of the Second Panel on Cost-Effectiveness & Medicine
Four video clips from the Recommendations of the Second Panel on Cost-Effectiveness & Medicine including:Part 1: Overview and Key RecommendationsPart 2: Components of the Cost-Effectiveness Ratio, Discussion PanelPart3: Conducting and Implementing CEAs, CEAs and Policy ConsiderationsPart 4: […]
Country-Level Cost-Effectiveness Thresholds
This report was conducted to estimate the cost-effectiveness thresholds (CETs) based on opportunity cost for a wide range of low to middle-income countries, which in the past have not had opportunity-cost-based CETs available. These estimates can provide a useful input to inform resource allocation […]
Health Economics Limited Impact on Funding
In a response to high cost treatments in health care, cost-effectiveness analysis, presented as cost per quality-adjusted life-years has emerged as a controversial subject. This report was conducted to assess and discuss the impact of economic evaluation in decisions on what to fund in four European […]
Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?
Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16) […]
4 Reasons Why the U.S. Rejects the European Healthcare Approach
It's clear the American healthcare system has long been in need of a total and complete overhaul. Many look to other countries who have succeeded in healthcare reform, however, others are calling for a distinctly American approach. What would that look like? Why is America so against the European, […]
ICER Releases Document on Osteoporosis Treatments
The Institute for Clinical and Economic Review (ICER) recently posted a draft scoping document reporting on the treatments for osteoporosis, which will be open for public comment until December 23, 2016. The report is expected to evaluate the comparative clinical effectiveness of abaloparatide, […]
Tis the Season for Value Assessment Frameworks!
In the September/October 2016 issue of Value & Outcomes Spotlight, David Thompson, PhD, addressed the multiple value assessment frameworks. Although very similar, the different frameworks have been created with different stakeholders best interest in mind. Read more here. (Source: Value & […]
NPC President Speaks on the Election and Value in Health Care
National Pharmaceutical Council (NPC) President, Dan Leonard, recently addressed the importance of capturing and communicating the value of ground-breaking new medicines -regardless of the next administration's health policy. Read more here. (Source: Dan Leonard, Morning Consult, 11/17/16) […]
Download Your Copy of Trends – Reinventing Medical Affairs
In this mini-magazine, eyeforpharma explores why MSLs need to get in touch with their emotions to engage with impact and delves into the changing face of medical affairs. Dr Ameet nathwani, CMO at Sanofi discusses the burgeoning role of medical affairs and the need for continuous, cost-effective […]
Agenda Now Available for 2nd Panel on CEA Conference
The full agenda is now available for the 2nd Panel on CEA conference (available below). This one-day conference on December 7, 2016 at the National Academy of Sciences in Washington DC will highlight the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine. The […]
NICE Plans a Fast Track for Cost-Effective Meds
The National Institute for Health and Care Excellence (NICE) recently announced the possibility of its most cost effective new drug recommendations to receive a fast track thru the National Health Service (NHS). Read more here. (Source: Ben Hirschler, Reuters, 10/13/16) […]
ICER Reviews Atopic Dermatitis Treatments
The Institute for Clinical and Economic Review (ICER) will be developing a report assessing the comparative clinical effectiveness and value of emerging therapies for the treatment of atopic dermatitis. Find out more here. (Source: ICER, 10/19/16) […]
NICE to Charge up to $282,000 for New Drug Assessments
The UK's National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16) […]
PhRMA Continues Critique of ICER Drug Pricing Studies
The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. […]
ICER to Partner with University of Colorado Skaggs School of Pharmacy
The University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and the Institute for Clinical and Economic Review (ICER) have formed a partnership to leverage CU Skaggs School of Pharmacy’s expertise in economic modeling of pharmaceutical interventions to support ICER’s growing […]
What’s Next for Cost-Effectiveness Analysis?
Since the seminal work of Weinstein and Stason2 in 1977, thousands of cost-effectiveness analyses (CEAs) have been performed to evaluate diagnostic and therapeutic strategies in virtually all disciplines of medicine. Concern about a lack of methodological standards prompted the US Public Health […]
Second Panel on Cost-Effectiveness in Health and Medicine
The Second Panel on Cost-Effectiveness in Health and Medicine was formed in 2012 to review the current status of the field of cost-effectiveness analysis and developed a new set of recommendations. Find out more about major changes made here. (Source: The Journal of the American Medical Association, […]
Evaluating Technologies Found Cost Effective at Zero Price
This article explains why some technologies may fail to demonstrate cost effectiveness even when the acquisition price is set to zero, raising both methodological and ethical questions for health technology assessment (HTA) agencies. Learn more here. (Source: Sarah Davis, Dr. Ron Akehurst, Health […]
Themed Value in Health focuses on Value
Check out this issue of Value in Health where they introduce their first themed section, focusing on value. The lead paper by Lou Garrison provides an overview of the topic and describes how cost-effectiveness analyses and pharmaconomics could play a central role in defining and assessing value. […]
One-Day Conference – Second Panel on Cost-Effectiveness in Health and Medicine
This one-day conference, on December 7, 2016, will be highlighting the second panel's findings and recommendations on cost-effectiveness in health and medicine. Registration is now available for in-person conference, or webcast version. Learn more here. (Source: Society for Medical Decision Making, […]
CDF May Drop Two Drugs Deemed Not Cost Effective
The National Institute for Health and Care Excellence (NICE) recently found two drugs, everolimus for advanced breast cancer, and ibrutinib for relapsed or refractory mantle cell lymphoma, to not be cost effective. The two drugs may not be available through the Cancer Drugs Fund (CDF) much longer. […]
3 Critical Components to Evaluating the Quality of a Model
Predictive modeling is the process of using data to predict an unknown event, and there is a growing body of research focused on building models to predict the decision-making of HTA agencies. However, not all models are created equal. Learn about 3 components that are critical to evaluating the […]
